Study Findings Support Furtherance of GED-0507 for IPF

Study Findings Support Furtherance of GED-0507 for IPF

307914

Study Findings Support Furtherance of GED-0507 for IPF

GED-0507, Nogra Pharma’s experimental therapy, significantly reduced the levels of pro-inflammatory and pro-scarring molecules, while suppressing the maturation of myofibroblasts — the main drivers of lung scarring (fibrosis) — to a similar or greater extent as two approved anti-fibrotic therapies. These findings, based on data from mice with induced pulmonary fibrosis (PF) and lab-grown human lung cells, shed light on the mechanisms behind GED-0507’s previously reported ability to lessen lung fibrosis in a mouse model. Together, the…

You must be logged in to read/download the full post.